Show simple item record

Galantamine protects against synaptic, axonal, and vision deficits in experimental neurotrauma

dc.contributor.authorNaguib, Sarah
dc.contributor.authorBernardo-Colon, Alexandra
dc.contributor.authorCencer, Caroline
dc.contributor.authorGandra, Neha
dc.contributor.authorRex, Tonia S.
dc.identifier.citationSarah Naguib, Alexandra Bernardo-Colón, Caroline Cencer, Neha Gandra, Tonia S. Rex, Galantamine protects against synaptic, axonal, and vision deficits in experimental neurotrauma, Neurobiology of Disease, Volume 134, 2020, 104695, ISSN 0969-9961,en_US
dc.description.abstractOur goal was to investigate the neuroprotective effects of galantamine in a mouse model of blast-induced indirect traumatic optic neuropathy (bITON). Galantamine is an FDA-approved acetylcholinesterase inhibitor used to treat mild-moderate Alzheimer's disease. We exposed one eye of an anesthetized mouse to repeat bursts of over-pressurized air to induce traumatic optic neuropathy. Mice were given regular or galantamine-containing water (120 mg/L) ad libitum, beginning immediately after blast and continuing for one month. Electroretinograms and visual evoked potentials were performed just prior to endpoint collection. Histological and biochemical assessments were performed to assess activation of sterile inflammation, axon degeneration, and synaptic changes. Galantamine treatment mitigated visual function deficits induced by our bITON model via preservation of the b-wave of the electroretinogram and the N1 of the visual evoked potential. We also observed a reduction in axon degeneration in the optic nerve as well as decreased rod bipolar cell dendritic retraction. Galantamine also showed anti-inflammatory and antioxidant effects. Galantamine may be a promising treatment for blast-induced indirect traumatic optic neuropathy as well as other optic neuropathies.en_US
dc.description.sponsorshipDoD W81XWH-15-1-0096, W81XWH-17-2-0055, NEI R01 EY022349, NEI P30 EY008126, NIA R01 NS094595, (VEI) Research to Prevent Blindness Unrestricted Funds, Ret. Maj. General Stephen L. Jones, MD Fund, Mark Pigott Fund, Potoscnak Family-CSC Research Fund, Ayers Research Fund in Regenerative Visual Neuroscience, NEI 5T32EY007135 (VVRC) P30 grant number (S. Naguib), NEI U24 EY29893.en_US
dc.publisherNeurobiology of Diseaseen_US
dc.rightsThis article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.
dc.subjectBlast injuryen_US
dc.subjectOptic nerveen_US
dc.subjectVisual evoked potentialen_US
dc.subjectOxidative stressen_US
dc.subjectIndirect traumatic optic neuropathyen_US
dc.titleGalantamine protects against synaptic, axonal, and vision deficits in experimental neurotraumaen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record